s&o logo
  • News
  • Trade Ideas
  • Education
  • Community
Sign Up!
News

AGBA Group shares move over 100% higher on merger with Triller

April 18, 2024 George Levine No comments yet
podcasters

AGBA Group (AGBA) stock is trading 114.7% higher at $0.86 Thursday afternoon after the company and Triller announced they entered into a definitive merger agreement to combine.

AGBA Group, a “one-stop financial supermarket” in Hong Kong, and Triller, an AI-driven social video platform, will combine to a company valued at roughly $4 billion on a pro-forma basis. At closing, Triller will be a wholly-owned subsidiary of AGBA.

The aim of the merger is to “transform global digital ecosystems” by combining AGBA’s financial experience and Triller’s AI-driven content creation and SaaS capabilities.

The Business Combination will also effectively result in the combined entity having one of the largest creator shareholder bases globally, including notable artists, influencers, and institutions such as the D’Amilio Family, Wiz Kalifa, Universal Music, Sony Music, Warner Music, Christina Aguilera, Marshmello, Ty Dolla $, Falcon, David Grutman, Shawn Gee, Des Bryant, Snoop Dogg, Tim Draper, Swizz Beats, Timbaland, Pegasus, Superbrands, Top Dawg, The Weeknd, Kendrick Lamar, Pitbull, TI, and Jake Paul.

AGBA Group

Bobby Sarnevesht will be the Triller CEO for the combined entity post-merger, Bob Diamond will be the Group Chairman, and Wing-Fai Ng will be the Group CEO. AGBA stockholders will own 20% of the combined company, while Triller stockholders will own the remaining 80% of the combined company.

AGBA Group saw a heavy increase in session volume and volatility following the announcement. The company has a 52-week high of $5.37 and a 52-week low of $0.32.

  • AGBA
  • M&A

Post navigation

Previous
Next

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Search

Categories

  • Education (15)
  • Featured (46)
  • News (85)
  • Trade Ideas (39)

Recent posts

  • FDA Closes Inspection of BioXcel’s TRANQUILITY II Trial Site, Reinforcing Data Integrity
  • Telomir Pharmaceuticals Breakthrough in Silver-Based Medicine
  • flyExclusive to Acquire Jet.AI’s Aviation Business in Strategic Expansion

Tags

BDRX CDT Conduit Conference Call CURR CURRENC Earnings Evergreen GH Research GHRS Grail GRAL HOLO IINN Inspira Technologies Interview IPWR JTAI KULR LCID Litigation LLY Lucid Motors M&A MedTech MicroCloud Movers MSTR My Size MYSZ News NLSP Novo Nordisk NVO Options Partnerships QNTM Quantum BioPharma Stock Market Stocks TAOP TELO Telomir Pharmaceuticals Traws Pharma TRWS

Continue reading

Featured, News, Trade Ideas

flyExclusive to Acquire Jet.AI’s Aviation Business in Strategic Expansion

February 14, 2025 Elisa Clay No comments yet

flyExclusive (NYSE American: FLYX), a leading provider of premium jet charter experiences, has entered into a definitive agreement to acquire the aviation business of Jet.AI (NASDAQ: JTAI). The deal will allow flyExclusive to expand its fleet and market presence while enabling Jet.AI to transition into a pure-play AI solutions company. Under the terms of the […]

Featured, News, Trade Ideas

NLS Pharmaceutics and Kadimastem Move Closer to Merger Approval

January 31, 2025 Elisa Clay No comments yet

NLS Pharmaceutics (Nasdaq: NLSP) and Kadimastem (TASE: KDST) have reached a key milestone in their planned merger after Kadimastem’s shareholders approved the deal in a special general meeting. The merger aims to create a Nasdaq-listed biotechnology company with a strong portfolio of treatments for neurodegenerative diseases and diabetes. NLS is now preparing to hold its […]

News, Trade Ideas

Roche Acquires Poseida Therapeutics in a $1.5 Billion Deal

November 26, 2024 Elisa Clay No comments yet

In a strategic acquisition set to advance its cell therapy capabilities, Roche Holdings, Inc. announced its acquisition of Poseida Therapeutics (PSTX) for up to $13 per share, amounting to an equity value of approximately $1.5 billion. The transaction includes $9.00 per share in cash at closing, alongside a contingent value right (CVR) of up to […]

s&o logo

Our primary goal is to empower retail investors with helpful news, guides and trading ideas.

Helpful Links
  • News
  • Trade Ideas
  • Education
  • Community
Resources
  • Privacy Policy
  • Terms & Conditions
  • Contact
Get in touch
  • Email us!

© Copyright 2024, stocks&options. All Rights Reserved.